PCM
NVCR icon

Prelude Capital Management’s NovoCure NVCR Stock Holding History

Prelude Capital Management’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-600
Closed -$67K – 1767
2020
Q3 		$67K Hold
600
– – ﹤0.01% 1040
2020
Q2 		$36K Buy
+600
New +$39.5K ﹤0.01% 1249

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
NA
Nordwand Advisors Radnor, Pennsylvania $572M AUM 23.09% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Prelude Capital Management's NVCR Position: Q3 2024 in Review

Prelude Capital Management sold out of NovoCure (NVCR) in Q3 2024, closing a stake of 12,471 shares — an estimated $214K sold.

Prelude Capital Management first reported a position in NVCR in Q3 2016 and held it in 13 quarters. The position peaked at $1.38M in Q3 2018. 225 funds tracked by Wall St. Rank hold NVCR as of Q3 2024.

  • Prelude Capital Management reported no remaining NovoCure position as of Q3 2024 after selling out during the quarter.
  • Prelude Capital Management sold 12,471 NovoCure shares in Q3 2024, an estimated $214K.
  • Prelude Capital Management first reported a position in NovoCure in Q3 2016 and held it in 13 quarters.
  • Prelude Capital Management's NovoCure position peaked at $1.38M in Q3 2018.
  • 225 funds tracked by Wall St. Rank held NovoCure as of Q3 2024.

Based on Prelude Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.